Optipharm.CO.,LTD (KOSDAQ:153710)
South Korea · Delayed Price · Currency is KRW 4,615.00
+135.00 (3.01%)
At close: Jul 31, 2026
Optipharm.CO.,LTD Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 22,788 | 22,345 | 19,636 | 17,373 | 16,008 | 14,258 |
Revenue Growth | 12.51% | 13.79% | 13.03% | 8.52% | 12.27% | 9.29% |
Gross Profit Gross Profit Growth | 5,786 | 5,587 | 4,896 | 4,195 | 3,715 | 3,736 |
Operating Income Operating Income Growth | -2,003 | -2,414 | -2,452 | -2,631 | -2,188 | -4,505 |
Net Income Net Income Growth | -2,115 | -2,499 | -2,357 | -2,437 | -2,045 | -3,080 |
Earnings Per Share EPS Growth | -143.97 | -170.36 | -161.00 | -166.00 | -140.00 | -212.00 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Animal Medicine Animal Medicine Growth | 10,112 | 9,411 | 9,185 | 7,463 | 6,713 |
Animal Disease Diagnosis Animal Disease Diagnosis Growth | 5,530 | 4,404 | 3,753 | 3,820 | 3,485 |
Bacteriophage Bacteriophage Growth | 2,042 | 1,900 | 1,735 | 1,639 | 1,589 |
Medipig Medipig Growth | 1,684 | 1,470 | 1,276 | 1,136 | 1,084 |
Other Other Growth | 269.14 | 187.01 | 60.32 | 198.99 | 175 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 8,798 | 9,878 | 14,231 | 15,651 | 16,621 | 22,106 |
Total Debt Total Debt Growth | 10,414 | 10,550 | 11,009 | 10,046 | 7,724 | 5,979 |
Net Cash (Debt) Net Cash Growth | -1,616 | -671.93 | 3,223 | 5,605 | 8,897 | 16,126 |
Net Cash Growth | - | - | -42.50% | -37.00% | -44.83% | -8.83% |
Net Cash Per Share Net Cash Per Share Growth | -109.99 | -45.80 | 220.17 | 381.82 | 609.19 | 1110.10 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -707.18 | -1,555 | -595.5 | -1,723 | -2,396 | -1,969 |
Capital Expenditures CapEx Growth | -1,182 | -2,507 | -1,677 | -1,672 | -4,572 | -725.18 |
Free Cash Flow Free Cash Flow Growth | -1,889 | -4,062 | -2,273 | -3,395 | -6,968 | -2,695 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 25.39% | 25.01% | 24.93% | 24.15% | 23.21% | 26.20% |
Operating Margin | -8.79% | -10.80% | -12.49% | -15.14% | -13.67% | -31.59% |
Pretax Margin | -9.28% | -11.18% | -12.00% | -14.03% | -12.77% | -21.60% |
Profit Margin | -9.28% | -11.19% | -12.00% | -14.03% | -12.77% | -21.60% |
FCF Margin | -8.29% | -18.18% | -11.58% | -19.54% | -43.53% | -18.90% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 3.01 | 3.35 | 3.47 | 5.94 | 6.42 | 9.63 |